Kilitch Drugs shareholders overwhelmingly approve all AGM resolutions

Kilitch Drugs (India) Ltd. held its 33rd annual general meeting on Friday, September 26, 2025, where all proposed resolutions were duly approved by the company's members. The meeting included remote e-voting and e-voting facilities, with M/s. Deep Shukla & Associates appointed as the scrutinizer.

For ordinary business item no. 01, concerning the adoption of financial statements, 99.99% of votes cast were in favor. The re-appointment of Bhavin Mehta as a director (item no. 02) received 99.99% of votes in favor. The re-appointment of Mukund Mehta as managing director (item no. 03) and the continuation of Vasudev Krishna Murti as an independent director (item no. 04) also secured 99.99% of votes in favor.

Additional resolutions, including the appointment of M/s Deep Shukla & Associates as secretarial auditor (item no. 05) and the ratification of remuneration to the cost auditor (item no. 07), each received 99.99% of votes in favor. Resolution item no. 06, to waive off PLI given to executive directors, garnered 99.9061% of votes in favor. Total votes polled across all resolutions consistently showed a high percentage in favor, ranging from 99.9061% to 99.99%.